June 8, 2015Acorda Therapeutics Inc • August 7th, 2015 • Biological products, (no disgnostic substances) • New York
We are delighted to present this letter agreement, setting out the terms of your continued employment with Acorda Therapeutics, Inc. (the "Company") as Chief Medical Officer. If these terms are acceptable, please sign and date the copy of this letter provided herewith and return it to me at your first convenience. If you accept the terms offered herein, this Agreement shall be deemed to be effective as of June 8, 2015 (the "Effective Date").
FIRST AMENDMENT TO LEASELease • August 7th, 2015 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT TO LEASE (this “First Amendment”) is entered into as of this 21st day of May, 2015 (the “First Amendment Date”), by and between BMR-ARDSLEY PARK LLC, a Delaware limited liability company (“Landlord”), and ACORDA THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 7th, 2015 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • Massachusetts
This EXECUTIVE EMPLOYMENT AGREEMENT (the "Agreement"), made as of this 27th day of December 2010, is entered into by Corregidor Therapeutics, Inc., a Delaware corporation with its principal place of business at 384 Powder Mill Road, Concord, Massachusetts 01742 (the "Company"), and Rick Batycky, residing at 19 Bernard Street, Newton, Massachusetts 02461 (the "Executive").
FIRST AMENDMENT TO EXECUTIVE EMPOYMENT AGREEMENTExecutive Empoyment Agreement • August 7th, 2015 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT (the "Amendment'') to the Executive Employment Agreement dated as of December 27, 2010 (the "Batycky Employment Agreement") entered into between Civitas Therapeutics, Inc. (f/k/a Corregidor Therapeutics, Inc.), a Delaware corporation (the "Company") and Rick Batycky (the "Executive"), is entered into by the Company and the Executive as of June 27, 2013. Capitalized terms not defined in this Amendment shall have the meanings ascribed to them in the Batycky Employment Agreement.
AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGERAgreement and Plan of Merger • August 7th, 2015 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
This Amendment No. 1 (the "Amendment") to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 15, 2012, by and among Acorda Therapeutics, Inc., a Delaware corporation ("Parent"), ATI Development Corp., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Neuronex, Inc., a Delaware corporation (the "Company"), and Moise A. Khayrallah, as the Stockholders’ Representative is entered into effective as of July 27, 2015 (the “Amendment Date”). Capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings given to such terms in the Merger Agreement.
EXECUTION VERSION CONFIDENTIAL SECOND AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENTEmployment Agreement • August 7th, 2015 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances)
THIS SECOND AMENDMENT (the "Amendment") to the Executive Employment Agreement dated as of December 27, 2010, as amended June 27, 2013 (the "Employment Agreement") entered into between Civitas Therapeutics, Inc. (f/k/a Corregidor Therapeutics, Inc.), a Delaware corporation (the "Company") and Rick Batycky (the "Executive"), is entered into by the Company and the Executive as of June 30, 2014 (the "Amendment Date"). Capitalized terms not defined in this Amendment shall have the meanings ascribed to them in the Employment Agreement.
